EpiVax Adds AI-Powered Immunogenicity Prediction to Its Biotherapeutics Platform
EpiVax is upgrading its computational immunology platform with AI-enabled models designed to give drug developers a more precise view of how the human immune system may respond to biotherapeutic candidates. The latest release of ISPRI combines an updated JanusMatrix model, a new tolerance-adjusted immunogenicity score and an enhanced anti-drug antibody prediction model, pushing computational assessment…
